The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Berenberg trims Novo Nordisk view as Eli Lilly’s oral pipeline shifts focus to pills
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 12, 2:39 PM EDT

Berenberg trims Novo Nordisk view as Eli Lilly’s oral pipeline shifts focus to pills

In a note cited by Yahoo Finance, Berenberg reduced its stance on Novo Nordisk while arguing that the “oral market” narrative has moved, with Eli Lilly positioned as the main beneficiary.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly’s push toward oral weight-loss and diabetes therapies is reshaping how some analysts frame competition in the booming GLP-1 drug class, according to a market update circulated by Yahoo Finance on Aug. 12, 2026.

The update points to a Berenberg reassessment of Novo Nordisk, suggesting that the previous upside case tied to a pill version of Novo’s blockbuster weight-loss drug Wegovy has already largely been “played out.” In the same framing, Berenberg appears to shift incremental expectations to Eli Lilly’s efforts to win share in the oral segment.

While the market narrative has centered on injections, an oral option matters because it can change how payers and patients think about access and convenience. The Yahoo Finance update characterizes the competitive picture as moving from “how big is the pill opportunity” to “who benefits most if the oral market scales.”

Berenberg’s positioning, as summarized in the Yahoo Finance item, implies that valuation and sentiment for Novo Nordisk are less dependent on the near-term prospect of Wegovy tablets than they were previously. The update also states that, in Berenberg’s view, the valuation multiple for Novo is now around the “European pharma average,” pointing to less enthusiasm than investors previously priced in.

The GLP-1 sector has undergone rapid expectation shifts over the past two years as companies have raced to differentiate on efficacy, tolerability, dosing convenience, and manufacturing scale. Oral GLP-1 programs are generally treated as a potential accelerant because a tablet could lower the friction of long-term use compared with injections, potentially expanding the addressable market.

Eli Lilly, which is the named beneficiary in the Berenberg framing, has become a focal point for investors watching whether an oral format can deliver comparable benefit while maintaining acceptable safety and adherence. The Yahoo Finance item does not provide detailed trial readouts in the excerpt used for this editorial packet, but it does connect Lilly’s oral strategy to a rebalancing of competitive expectations within the space.

What is not clear from the Yahoo Finance summary is the specific magnitude of Berenberg’s adjustment, such as any numerical changes to targets, price objectives, or formal rating labels. The update also does not disclose timing details for oral product commercialization, nor does it cite particular clinical endpoints in the excerpt provided.

Why It Matters

  • Expectations for oral GLP-1 competition appear to be moving from “possible upside” to relative winners and losers, which can influence how investors price pipeline risk.
  • If analysts conclude that pill upside for one incumbent has diminished, valuation support can shift toward companies with stronger oral momentum.
  • Multiple compression or normalization language, such as “European pharma average,” can announcement a change in how the market interprets growth visibility versus uncertainty.
  • The industry’s focus may increasingly turn to execution details for oral formulations, including adoption barriers and manufacturing scale.

Sources

Key Facts

  • A Yahoo Finance market update on Aug. 12, 2026 discusses a Berenberg note adjusting its stance on Novo Nordisk.
  • The update’s framing says Wegovy pill upside has “already played out,” reducing incremental optimism for Novo.
  • Berenberg is described as viewing Eli Lilly as the key player for the “oral market.”
  • The update states that, in Berenberg’s view, Novo Nordisk’s multiple is now around the European pharma average.

Healthcare Related